ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

nemolizumab

Also written as “Nemolizumab”, “Nemolizumab 30 mg” and “nemolizumab (CIM331)”.

Its studies are mostly in Dermatitis, Atopic · Prurigo · Scleroderma, Systemic · Pruritus · Renal Insufficiency, Chronic, led by 4 companies.

Drug pageNemolizumab: every studyAll 26 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jun 11, 201923 company-led studies, 6 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Galderma Groupits history only205 open or runningphase 3since Jun 11, 2019Mar 29, 2017Dec 2026phase 2 · NCT07074977
Hoffmann-La Roche10 open or runningphase 2since Oct 31, 2013Oct 31, 2013none ahead
Maruhoits history only10 open or runningphase 2since Jan 17, 2022Jan 17, 2022none ahead
The Skin Center Dermatology Groupits history only11 open or runningphase 4since Feb 1, 2026Feb 1, 2026Jun 2027phase 4 · NCT07396168

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Hoffmann-La Roche only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 31, 2013First study: phase 2 study in Dermatitis, AtopicFirst studyNCT01986933 · 264 enrolled · United States

TargetBeta

IL31RA →read by rule
“Interleukin-31 receptor subunit alpha inhibitor”ChEMBL 37, by rule

Other programs on IL31RA

ProgramCompanyFurthest phaseStudies
ABBV-313AbbViephase 11

Studies

The one study Hoffmann-La Roche leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01986933Dermatitis, Atopic · United States2CompletedApr 2015264

How it is read

Names in the registry

  • “Nemolizumab”, 20 entries
  • “Nemolizumab 30 mg”, 2 entries
  • “nemolizumab”, 2 entries
  • “nemolizumab (CIM331)”, 1 entry
  • “CD14152 Dose A”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.